ImpediMed
(ASX:IPD), a global provider of medical technology, announced its study has been published in a peer-reviewed medical journal.
The study involves the effectiveness of L-Dex for the screening, intervention and prevention of disease progression.
The 6-year study was conducted at the Nashville Breast Centre, comprising retrospective analysis and examination of nearly 600 breast cancer patients at risk of developing lymphodema.
CEO and Managing Director of ImpediMed Richard Carreon said the published study adds to the peer-reviewed evidence supporting the clinical impact of using L-Dex.
ImpediMed was the first company to receive FDA approval to clinically assess lymphodema for its L-Dex device.
Shares in ImpediMed
(ASX:IPD) are trading 6.33 per cent lower to $0.74.
